(Paris:ABVX),(NasdaqGM:ABVX), Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in […]

Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment GlobeNewswire December 18, 2025 MOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI

Applied Digital Sets Fiscal Second Quarter 2026 Conference Call for Wednesday, January 7, 2026, at 5:00 p.m. Eastern Time GlobeNewswire December 18, 2025 DALLAS, Dec. 18, 2025 (GLOBE NEWSWIRE) — Applied Digital Corporation (Nasdaq: APLD) (“Applied Digital” or the “Company”), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocations services for

Medline Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire December 18, 2025 NORTHFIELD, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) — Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its upsized initial public offering of 248,439,654 shares of its Class A common stock

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 18, 2025 SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on

Mission Produce(R) Announces Leadership Succession and Provides Update on Board Refreshment Initiative GlobeNewswire December 18, 2025 Founder & CEO Steve Barnard to Transition to Executive Chairman of the Board; President and COO John Pawlowski to Become CEO at the close of the Annual Meeting of Shareholders in April 2026 Board Refreshment Initiative Underway -Three New

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 18, 2025 CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease Event to be held January 6th, 2026, at 10 a.m. EST GlobeNewswire December 18, 2025 BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 18, 2025 SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held

Parsons Names John Martinez as the Company's Next Chief Legal Officer GlobeNewswire December 18, 2025 CHANTILLY, Va., Dec. 18, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN) has named proven executive and legal expert John Martinez as the company's next chief legal officer (CLO), effective February 16, 2026. The announcement follows the notification by current CLO